Structures by: Mishnev A.
Total: 39
C15H22O3
C15H22O3
Journal of natural products (2020) 83, 6 2004-2009
a=5.8085(3)Å b=7.3835(4)Å c=33.4086(17)Å
α=90° β=90° γ=90°
C22H27NO7
C22H27NO7
Journal of natural products (2020) 83, 6 2004-2009
a=18.7540(2)Å b=9.07510(10)Å c=26.1928(3)Å
α=90° β=102.7500(10)° γ=90°
C12H10FNO2
C12H10FNO2
Organic & biomolecular chemistry (2020) 18, 7 1384-1388
a=9.35850(10)Å b=13.58740(10)Å c=17.46810(10)Å
α=103.3740(10)° β=91.6650(10)° γ=93.4330(10)°
Diltiazem
C22H26N2O4S
CrystEngComm (2016) 18, 7 1235
a=9.3387(2)Å b=13.9027(4)Å c=16.5550(5)Å
α=90.00° β=90.00° γ=90.00°
Dilteazem acetylsalicylate hydrate
C22H27N2O4S,C9H7O4,H2O
CrystEngComm (2016) 18, 7 1235
a=9.9411(4)Å b=10.7606(3)Å c=28.5926(11)Å
α=90.00° β=90.00° γ=90.00°
Diltiazem nicotinate
C22H27N2O4S,C6H4NO2
CrystEngComm (2016) 18, 7 1235
a=8.7897(2)Å b=6.17260(10)Å c=25.1531(7)Å
α=90.00° β=91.5255(11)° γ=90.00°
Diltiazem L-Malate
C26H32N2O9S
CrystEngComm (2016) 18, 7 1235
a=5.89620(10)Å b=9.0320(2)Å c=50.5074(10)Å
α=90.00° β=90.00° γ=90.00°
Propranolol oxalate methanol solvate (2:1:1)
2(C16H22NO2),C2O4,0.9(CH4O)
CrystEngComm (2015) 17, 47 9023
a=10.7741(2)Å b=11.3507(2)Å c=28.2413(6)Å
α=90.00° β=90.00° γ=90.00°
Propranolol maleate (1:1)
C16H22NO2,C4H3O4
CrystEngComm (2015) 17, 47 9023
a=9.2010(3)Å b=8.7153(3)Å c=24.7710(11)Å
α=90.00° β=94.6180(10)° γ=90.00°
Propranolol oxalate (2:1)
C16H22NO2,0.5(C2O4)
CrystEngComm (2015) 17, 47 9023
a=12.9928(6)Å b=6.4517(3)Å c=19.8420(13)Å
α=90.00° β=106.600(2)° γ=90.00°
Propranolol fumarate (2:1)
C16H22NO2,0.5(C4H2O4)
CrystEngComm (2015) 17, 47 9023
a=7.7989(3)Å b=9.1669(4)Å c=12.4724(6)Å
α=89.470(2)° β=75.754(2)° γ=76.412(3)°
Propranolol fumarate (1:1)
C16H22NO2,0.5(C4H4O4),0.5(C4H2O4)
CrystEngComm (2015) 17, 47 9023
a=8.6157(2)Å b=9.9155(2)Å c=13.1345(4)Å
α=97.3910(10)° β=102.2400(10)° γ=109.8990(10)°
C17H22NO4
C17H22NO4
CrystEngComm (2015) 17, 47 9023
a=8.1696(3)Å b=5.6053(2)Å c=18.9321(9)Å
α=90.00° β=98.820(2)° γ=90.00°
Xylazine hydrochloride A form
C12H17SN21Cl1
Acta Crystallographica Section B (2014) 70, 2 342-346
a=11.5870(3)Å b=8.7174(2)Å c=14.8813(4)Å
α=90.00000° β=115.1475(13)° γ=90.00000°
Xylazine hydrochloride Z form
C12H17N2S1Cl1
Acta Crystallographica Section B (2014) 70, 2 342-346
a=12.4500(5)Å b=11.6223(5)Å c=9.3622(4)Å
α=90.00000° β=97.410(3)° γ=90.00000°
Xylazine hydrochloride X form
C12H17SN21Cl1
Acta Crystallographica Section B (2014) 70, 2 342-346
a=12.1155(13)Å b=8.3857(7)Å c=13.5322(15)Å
α=90.00000° β=94.921(6)° γ=90.00000°
<i>catena</i>-Poly[[[diaqualithium]-μ-γ-cyclodextrin(1-)-[aqualithium]-μ-γ-cyclodextrin(1-)] pentadecahydrate]
C96H194Li2O98
Acta Crystallographica Section E (2020) 76, 3 349-353
a=15.00386(18)Å b=17.0413(2)Å c=17.64915(15)Å
α=117.0411(10)° β=96.8906(9)° γ=96.8281(10)°
3-Hydroxy-2-(4-hydroxy-3-methoxyphenylmethyl)-5,5-dimethylcyclohex-2-enone
C16H20O4
Acta Crystallographica Section E (2018) 74, 6 796-798
a=9.3504(3)Å b=13.6265(4)Å c=22.8790(9)Å
α=90° β=90° γ=90°
4-(Thien-2-yl)-2-methyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylic acid ethoxycarbonylphenylmethylester
C25H25NO5S
Acta Crystallographica Section E (2018) 74, 11 1577-1579
a=13.9560(4)Å b=8.2829(2)Å c=19.9532(6)Å
α=90° β=95.4750(10)° γ=90°
3-Amino-5,5-dimethyl-2-[(<i>E</i>)-2-nitroethenyl]cyclohex-2-en-1-one
C10H14N2O3
Acta Crystallographica Section E (2014) 70, 11 379-381
a=11.3545(3)Å b=18.1097(5)Å c=10.4689(3)Å
α=90.00° β=100.119(2)° γ=90.00°
2,2-Dimethyl-5-(2,4,6-trimethoxybenzyl)-1,3-dioxane-4,6-dione
C16H20O7
Acta crystallographica. Section C, Structural chemistry (2015) 71, Pt 9 752-758
a=9.8128(2)Å b=10.0235(2)Å c=30.4669(6)Å
α=90.00° β=90.00° γ=90.00°
5-(4-Hydroxy-3,5-dimethoxybenzyl)-2,2-dimethyl-1,3-dioxane-4,6-dione
C15H18O7
Acta crystallographica. Section C, Structural chemistry (2015) 71, Pt 9 752-758
a=22.9942(5)Å b=10.1840(2)Å c=26.9904(7)Å
α=90.00° β=112.1250(10)° γ=90.00°
3,6,6-Trimethyl-4-oxo-1-(pyridin-2-yl)-4,5,6,7-tetrahydro-1<i>H</i>-indazol-7-aminium chloride
C15H19N4O,Cl
Acta crystallographica. Section E, Crystallographic communications (2017) 73, Pt 12 1931-1936
a=13.5411(4)Å b=7.7421(2)Å c=19.2457(5)Å
α=90° β=130.493(2)° γ=90°
3,6,6-Trimethyl-4-oxo-1-(pyridin-2-yl)-4,5,6,7-tetrahydro-1<i>H</i>-indazol-7-aminium chloride monohydrate
C15H19N4O,Cl,H2O
Acta crystallographica. Section E, Crystallographic communications (2017) 73, Pt 12 1931-1936
a=10.1855(2)Å b=7.4951(2)Å c=20.7961(4)Å
α=90° β=100.5450(10)° γ=90°
(furosemide).(pentoxifylline)
C12H11ClN2O5S,C13H18N4O3
Acta Crystallographica Section C (2012) 68, 12 o488-o491
a=8.0948(2)Å b=9.3747(2)Å c=36.2910(10)Å
α=90.00° β=93.1280(10)° γ=90.00°
(furosemide).(pentoxifylline).(acetone)
C13H18N4O3,C12H11ClN2O5S,C3H6O
Acta Crystallographica Section C (2012) 68, 12 o488-o491
a=9.3099(2)Å b=9.5317(3)Å c=19.2653(7)Å
α=99.733(2)° β=96.057(2)° γ=109.197(3)°
(furosemide).(pentoxifylline).(water)
C12H11ClN2O5S,C13H18N4O3,H2O
Acta Crystallographica Section C (2012) 68, 12 o488-o491
a=8.4052(2)Å b=9.4494(3)Å c=19.6748(9)Å
α=92.6490(10)° β=99.170(2)° γ=111.4660(10)°
Pentoxifylline
C13H18N4O3
Acta Crystallographica Section E (2011) 67, 11 o2851
a=9.743(6)Å b=17.410(8)Å c=7.956(3)Å
α=90.00° β=90.89(2)° γ=90.00°
Pimobendan B form
C19H18N4O2
Acta Crystallographica Section E (2013) 69, 11 o1677
a=18.891(5)Å b=9.9619(5)Å c=9.5029(8)Å
α=90.00000° β=90.799(13)° γ=90.00000°
Tianeptine hydrochloride
C21H26ClN2O4S,Cl
Acta Crystallographica Section E (2012) 68, 11 o3136
a=9.5439(2)Å b=10.0910(2)Å c=13.1802(3)Å
α=104.4000(12)° β=101.5380(10)° γ=105.0180(11)°
Betulin 3,28-di-O-tosylate
C44H62O6S2
Acta Crystallographica Section E (2014) 70, 8 o879-o880
a=6.98240(10)Å b=18.2035(4)Å c=31.4449(9)Å
α=90.00° β=90.00° γ=90.00°
2,6-Dichloro-9-(2,3',5'-tri-<i>O</i>-acetyl-β-<i>D</i>-ribofuranosyl)-9<i>H</i>-purine
C16H16Cl2N4O7
Acta Crystallographica Section E (2014) 70, 2 o108-o109
a=10.1324(2)Å b=9.6887(3)Å c=10.5399(2)Å
α=90.00° β=106.537(2)° γ=90.00°
3-{3,5-Bis[(2-butoxyethoxy)carbonyl]-2,6-dimethyl-1,4-dihydropyridin-4-yl}- 1-[(3,4,5-trimethoxybenzoyl)methyl]pyridinium bromide
C37H51N2O10,Br
Acta Crystallographica Section E (2013) 69, 1 o58-o59
a=8.9501(2)Å b=12.4741(3)Å c=17.6994(5)Å
α=93.0570(10)° β=91.6580(10)° γ=108.0240(10)°
{(3a<i>R</i>,5<i>S</i>,6<i>R</i>,6a<i>R</i>)-5-[(<i>R</i>)-1,2-Dihydroxyethyl]-2,2-dimethyltetrahydrofuro[2,3-<i>d</i>][1,3]dioxol-6-yl}methyl methanesulfonate
C11H20O8S
Acta Crystallographica Section E (2014) 70, 5 o524-o525
a=5.57940(10)Å b=15.6118(3)Å c=8.0653(2)Å
α=90.00° β=98.9130(10)° γ=90.00°
3-Acetyl-2-methyl-4-(pyridin-3-yl)-1,4-dihydroindeno[1,2-<i>b</i>]pyridin-5-one
C20H16N2O2
Acta Crystallographica Section E (2013) 69, 5 o717
a=8.4361(3)Å b=8.8812(3)Å c=11.2582(4)Å
α=87.692(2)° β=71.022(2)° γ=89.210(2)°
C19H23N7O2S
C19H23N7O2S
The Journal of organic chemistry (2020) 85, 7 4753-4771
a=16.55130(10)Å b=9.66570(10)Å c=25.6444(2)Å
α=90° β=90° γ=90°
C18H21ClN4O2S
C18H21ClN4O2S
The Journal of organic chemistry (2020) 85, 7 4753-4771
a=6.2963(2)Å b=12.2014(3)Å c=12.3922(4)Å
α=89.249(2)° β=79.699(3)° γ=81.512(3)°
C21H32O2Si
C21H32O2Si
The Journal of organic chemistry (2019) 84, 6 3595-3611
a=10.7686(3)Å b=6.6244(2)Å c=15.1218(5)Å
α=90° β=110.361(2)° γ=90°
5-[4-(Diethylamino)benzyl]-2,2-dimethyl-1,3-dioxane-4,6-dione
C17H23NO4
Acta crystallographica. Section C, Structural chemistry (2015) 71, Pt 9 752-758
a=15.0721(4)Å b=11.3109(3)Å c=19.4443(4)Å
α=90.00° β=90.00° γ=90.00°